MAP's migraine drug Levadex hits all goals of first Phase III study
This article was originally published in Scrip
MAP Pharmaceuticals' inhaled acute migraine therapy candidate, Levadex (MAP0004), has met the four primary endpoints of relieving pain, nausea, and sensitivity to light and sound, in its first Phase III trial.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.